L
Lina Badimon
Researcher at Carlos III Health Institute
Publications - 746
Citations - 41283
Lina Badimon is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Medicine & Myocardial infarction. The author has an hindex of 86, co-authored 682 publications receiving 35774 citations. Previous affiliations of Lina Badimon include Pompeu Fabra University & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
The pathogenesis of coronary artery disease and the acute coronary syndromes (1).
TL;DR: The two hypotheses to explain the pathogenesis of atherosclerosis, the "incrustation" hypothesis and the "lipid" hypothesis, are now known.
Journal ArticleDOI
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli,Héctor Bueno,Robert A. Byrne,Jean-Philippe Collet,Francesco Costa,Anders Jeppsson,Peter Jüni,Adnan Kastrati,Philippe Kolh,Laura Mauri,Gilles Montalescot,Franz-Josef Neumann,Mate Petricevic,Marco Roffi,Philippe Gabriel Steg,Stephan Windecker,José Luis Zamorano,Glenn N. Levine,Lina Badimon,Pascal Vranckx,Stefan Agewall,Felicita Andreotti,Elliott M. Antman,Emanuele Barbato,Jean-Pierre Bassand,Raffaele Bugiardini,Mustafa Cikirikcioglu,Thomas Cuisset,Michele De Bonis,Victora Delgado,Donna Fitzsimons,Oliver Gaemperli,Nazzareno Galiè,Martine Gilard,Christian W. Hamm,Borja Ibanez,Bernard Iung,Stefan James,Juhani Knuuti,Ulf Landmesser,Christophe Leclercq,Maddalena Lettino,Gregory Y.H. Lip,Massimo F Piepoli,Luc Pierard,Markus Schwerzmann,Udo Sechtem,Iain A. Simpson,Miguel Sousa Uva,Eugenio Stabile,Robert F. Storey,Michal Tendera,Frans Van de Werf,Freek W.A. Verheugt,Victor Aboyans +54 more
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter,Stephan Achenbach,Stefan Agewall,Lina Badimon,Gonzalo Barón-Esquivias,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Scipione Carerj,Veronica Dean,Çetin Erol,Donna Fitzsimons,Oliver Gaemperli,Paulus Kirchhof,Philippe Kolh,Petros Nihoyannopoulos,Piotr Ponikowski,Marco Roffi,Antonio Vaz Carneiro,Stephan Windecker +34 more
TL;DR: No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.
Journal ArticleDOI
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.
TL;DR: This is the first in vivo, prospective evidence of the antiatherogenic effect of HDL-VHDL against preexisting atherosclerosis and suggests that it may be possible not only to inhibit progression but even to reduce established atherosclerotic lesions by HDL administration.
Journal ArticleDOI
Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.
TL;DR: The role of vascular injury in the pathogenesis of spontaneous and accelerated atherosclerosis, and the resultant cellular pathophysiologic responses, specifically, lipid accumulation, platelet aggregation, thrombus formation and smooth muscle cell proliferation, are discussed.